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Shortly after activation by either thrombin or the 
tethered ligand domain peptide SFLLRN, thrombin 
receptors  undergo  homologous  desensitization,  tempo- 
rarily losing  their ability to  respond  to  both  agonists. 
We have  examined  the role of  receptor  internalization 
and recycling in this process  using  receptor-directed 
antibodies as probes.  The results show within 1 min  of 
activation >85% of  the  approximately 200,000 throm- 
bin  receptors on megakaryoblastic human erythroleu- 
kemia (HEL) and CHRF-288 cells are sequestered  into 
endosomes via coated pits, after which the majority 
are transferred to lysosomes. This process does not 
require proteolysis of the receptor and occurs with 
sufficient speed  to  play  a  major  role  in  the  regulation 
of  thrombin  receptor  function.  Although  most  of  the 
internalized receptors are ultimately degraded, ap- 
proximately 25% return  to  the cell surface.  These re- 
cycled  receptors  are  in  a state in  which  they  can re- 
spond  to  SFLLRN  but  not  thrombin; nor do they self- 
activate despite  the  apparent  continued  presence  of  the 
tethered  ligand. In contrast  to  other G protein-coupled 
receptors,  which  are  internalized  and  then  recycled  in 
an  activatable state, recovery  of  the  thrombin  response 
occurs  only after the  expression on  the cell surface of 
adequate  numbers  of newly synthesized  receptors. 
Thrombin is a  serine protease that is able to evoke  biological 
responses from a variety of cells, including platelets. Recent 
evidence suggests that most, if not all, of these responses are 
mediated by a single class of cell surface receptors belonging 
to the family of G protein-coupled receptors (1, 2). Based 
upon cDNA sequencing, the human  platelet  thrombin recep- 
tor is thought to be formed by a single polypeptide chain with 
seven transmembrane domains and an extracellular N ter- 
minus. According to  current models, receptor activation oc- 
curs when thrombin cleaves the N  terminus between residues 
Arg” and Ser4’, exposing a  tethered ligand for the receptor 
(1,2). In support of this model, peptides containing the initial 
6 residues of the neo-N terminus,  SFLLRN, have been shown 
to mimic the effects of thrombin on platelets (1, 3-9) and 
antibodies directed against the tethered ligand domain have 
been shown to inhibit platelet activation by thrombin (10, 
11). 
One of the characteristics of cellular responses to thrombin 
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is that receptor activation produces a state of homologous 
desensitization in which the readdition of thrombin fails to 
evoke a second response (12-15). We have previously shown 
that desensitization affects responses to  the receptor-derived 
peptide SFLLRN, as well as thrombin (16, 17). Using the 
megakaryoblastic HEL’ cell line as  a model, we found that 
activation by either  thrombin or SFLLRN prevented a sub- 
sequent response to both agonists, even though responses to 
other agonists were preserved. Notably, recovery from the 
desensitized state occurred in two distinct phases. In  the first 
phase, which was detectable within 30 min and continued 
over several hours, there was a  partial (30-40%) recovery of 
responsiveness to  SFLLRN  but no recovery of the response 
to thrombin when the initial desensitization was caused by 
thrombin. When the initial desensitization was caused by 
SFLLRN, recovery of responsiveness to both agonists oc- 
curred at  the same time. This  first  phase of recovery  could  be 
delayed by inhibitors of serinelthreonine phosphatases but 
was unaffected by cycloheximide. In the second phase of 
recovery, which required as much as 20 h to complete, there 
was a full return of receptor responses to both  SFLLRN  and 
thrombin. This phase of recovery could be inhibited by  cyclo- 
heximide, suggesting that  it was at least partly due to  the 
synthesis of new receptors (17). 
These results suggested a model in which both receptor 
synthesis  and dephosphorylation play a role in the recovery 
of thrombin receptor function on desensitized cells.  However, 
it was unclear from those studies why cells desensitized by 
thrombin recover their ability to respond to SFLLRN in 
advance of their ability to respond to thrombin,  and whether 
this might be due to  the reactivation of previously inactivated 
receptors. It was also unclear whether receptor internalization 
might play a role in the regulation of receptor function,  as it 
appears to do for 8-adrenergic receptors (18, 19). To answer 
these questions, the present studies examine the effects of 
thrombin on the surface distribution, internalization, and 
recycling of thrombin receptors. The results show that acti- 
vated thrombin receptors, like @-adrenergic receptors, can be 
rapidly internalized. Some of these internalized receptors are 
eventually recycled to  the cell surface. However, in contrast 
to 8-adrenergic receptors, recycled thrombin receptors lose 
their capacity to respond to thrombin, even while recovering 
their ability to be activated by SFLLRN. 
EXPERIMENTAL  PROCEDURES 
antibodies against residues 42-55 (SFLLRNPNDKYEPF) of the 
Monoclonal Antibodies-The preparation of murine monoclonal 
The abbreviations used are: HEL cells, human erythroleukemia 
cells; CHRF-288 cells, Children’s Hospital Research Foundation cell 
line number 288; LH, lutropin hormone; LAMP, lysosome-associated 
membrane protein; FITC, fluorescein isothiocyanate; HIV, human 
immunodeficiency virus. 
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human thrombin receptor is described elsewhere (10). Based upon 
binding assays with peptide fragments, two of the antibodies, 
ATAP87 and ATAP138, are specific for epitope(s) within the se- 
quence NPNDKYEPF. The third, ATAP2, recognizes an epitope 
within SFLLRNPN. These antibodies bind to  the surface of intact 
platelets and inhibit  thrombin-induced  platelet  activation (10). An- 
tibody WEDEl5 was prepared against a peptide corresponding to 
thrombin receptor residues 51-64 (KYEPFWEDEEKNES)  and 
reacts  in binding assays with the immunizing peptide but not peptide 
SFLLRNPNDKYEPF. All four of these antibodies are of the IgGl 
subtype. The anti-transferrin receptor antibody RPN511 was ob- 
tained from Amersham Corp. Antibody H4A3, directed against the 
human lysosomal protein LAMP-1, was a gift from Dr. J. T. August 
(Johns Hopkins University, Baltimore, MD) (20). Monoclonal anti- 
bodies BA6 and A2A9 directed against CD9 and  the glycoprotein IIb- 
IIIa complex, respectively, are described elsewhere (21, 22). IgGl 
monoclonal antibodies that were used as isotype-matched negative 
controls included P3X63 (23), EH1, and DA6. The  latter two anti- 
bodies are reactive with the HIV-1 n e f  protein and HIV-2 gp120 
envelope molecules, respectively.' 
cells, CHRF-288 or HEL cells were incubated at 37 'C in the presence 
Immunofluorescence Microscopy-For surface staining of intact 
or absence of an agonist, washed once, and then incubated with 
primary antibody for 30 min at 4 "C. Afterward, the cells were washed 
again, incubated for 30 min at 4 "C with a 1:20 dilution of FITC- 
conjugated goat anti-mouse IgG (Tago, Burlingame, CA), washed, 
and  then fixed with 1% paraformaldehyde before being cytocentri- 
fuged onto glass slides for microscopy. For intracellular  staining, the 
cells were cytocentrifuged onto glass slides, fixed with metha- 
no1:acetone (50:50), and  then stained with an optimal  concentration 
of antibody. In the co-localization studies, the permeabilized cells 
were incubated with either the  anti-transferrin receptor antibody or 
the anti-LAMP antibody, followed by rhodamine-conjugated goat 
anti-mouse IgG (Tago). Antibody EH1 was then added as a blocking 
reagent, followed by FITC-conjugated antibody ATAPZ. 
Electron Microscopy-CHRF-288 cells were incubated with 50 nM 
thrombin at 37 "C. At various times (0-5 min)  aliquots were removed 
and added to a large volume of ice-cold medium. All further  manip- 
ulations were performed at 4 "C. The cells were washed by centrifu- 
gation and resuspended in cold medium containing  a 1: lOO dilution 
of antibody ATAP2 ascites. After 30 min the cells were washed several 
times and  then incubated with goat anti-mouse IgG adsorbed to 5- 
nm gold (Aurion, The Netherlands). After additional washing the cells 
were sedimented, fixed in 1% glutaraldehyde in 100 mM cacodylate 
buffer, pH 7.35, and embedded in Epon. Sections were stained with 
uranyl acetate and lead citrate and viewed in  a Zeiss EM10 microscope 
(24). 
Flow Cytometry-After incubation with the desired agonist for 
varying time intervals, CHRF-288 or HEL cells (2 X lo6 cells/ml) 
were  fixed in suspension in 1% paraformaldehyde, kept on ice for 30 
min and  then washed and resuspended in  staining buffer (phosphate- 
buffered saline, 0.02% sodium azide, 0.2% bovine serum albumin, pH 
7.4). Primary antibodies were added in the form of either undiluted 
hybridoma culture supernatant or an optimal dilution of ascites (1:400 
to 1:1,000). After 30 min the cells were washed again, incubated with 
a 1:40 dilution of FITC-labeled goat anti-mouse IgG (Tago) for an 
additional 30 min, and  then fixed in 4% paraformaldehyde for analysis 
on  a FACScan flow cytometer (Becton Dickinson, Mountain View, 
CA). 
Binding Studies-The binding of radioiodinated ATAP138 to 
CHRF-288 cells and HEL cells was quantitated essentially as de- 
scribed previously (10). In brief, the antibody was incubated with the 
cells (1 X 106/ml) for 20 min at 37  'C, after which aliquots of the cell 
suspension were sedimented through silicone oil to separate bound 
from free antibody. ["C]Inulin was used to correct for unbound 
antibody trapped within the cell pellet, although this correction 
proved to be  negligible. 
Other Methods and Materials-Human a-thrombin (~3 ,000  units/ 
mg)  was provided by Dr. J. Fenton (New York State Department of 
Health, Albany, NY). Peptides were prepared as described (4). CHRF- 
288 cells (25), which  were originally derived from a patient with acute 
megakaryoblastic leukemia, were a gift from Drs. M. Lieberman and 
D. Witte (University of Cincinnati College  of Medicine, Cincinnati, 
OH)  and were maintained  in RPMI 1640 medium with 20% fetal calf 
serum. HEL cells were obtained from the American Type Culture 
Collection (Rockville, MD) and maintained in RPMI 1640 medium 
J. Hoxie, unpublished obsenrations. 
with 10% fetal calf serum (16). Changes in the cytosolic free Ca2+ 
concentration were measured using Fura-2 as previously described 
(17). 
RESULTS 
Thrombin receptor desensitization and  internalization were 
studied with HEL cells (26) and CHRF-288 cells (251, two 
human cell lines with megakaryoblastic properties. The  HEL 
cell thrombin receptor has a nucleotide sequence that is 
identical to  that reported for Dami cells (1) except for the 
substitution of Leu for Valz3' and Cys for Serm  in the fourth 
and  seventh predicted transmembrane  domain^.^ The number 
of thrombin receptors on the surface of CHRF-288 and  HEL 
cells was determined using ATAP138, a monoclonal antibody 
directed against the tethered ligand domain of the thrombin 
receptor (the specificities of the various monoclonal antibod- 
ies used in these  studies  are described in greater detail under 
"Experimental Procedures"). On average, ATAP138 bound to 
209,000 f 6,000 sites  on CHRF-288 cells (Fig. lA) and 160,000 
2 40,000 sites on HEL cells (data  not shown). Since the same 
antibody binds to approximately 1,800 sites/cell on platelets 
(10) and since HEL and CHRF-288 cells have roughly 10 
times the diameter  and 100 times the surface area of platelets, 
the density of thrombin receptors on the two cell lines appears 
to be similar to platelets. 
Data showing the response of HEL cells to thrombin  and 
the desensitization of the HEL cell thrombin receptor by 
thrombin  and  SFLLRN have been presented elsewhere (16, 
17). Comparable results with CHRF-288 cells are shown in 
Fig. 1. As was seen with HEL cells, both  thrombin  and  the 
SFLLRN peptide caused a  transient increase in the cytosolic 
free Ca2+ concentration in CHRF-288 cells (Fig. 1B). This 
response was no longer present when the cells were incubated 
with thrombin for 10 min, washed, and then rechallenged 
immediately with either thrombin or SFLLRN (Fig. 1C). 
Three  hours  later, the cells were still unresponsive to  throm- 
bin but had partially regained their ability to respond to 
SFLLRN (Fig. 1D). 
Loss of Receptors from the Cell Surface following Actiua- 
tion-The distribution of thrombin receptors on the surface 
of CHRF-288 cells was examined by fluorescence microscopy 
using antibody ATAP2, which is also directed against the 
tethered ligand domain of the receptor N  terminus. On resting 
cells ATAP2 binding sites were present on all cells and 
uniformly distributed across the cell surface (Fig. 2 A ) .  How- 
ever, after exposure to thrombin for 10 min little or no 
antibody binding could be detected (Fig. 2B) .  An identical 
loss of ATAP2 binding sites occurred when the cells were 
incubated with SFLLRN,  rather  than  thrombin  (not shown), 
but  the binding of monoclonal antibodies directed against the 
plasma membrane protein CD9 (Fig. 2, C and D) and the 
glycoprotein IIb-IIIa complex (not shown) was unaffected by 
either  thrombin or SFLLRN. 
Flow cytometry was used to  quantitate  the ffects of throm- 
bin on antibody binding to  the surface of CHRF-288 cells. 
Exposure to thrombin for 10 min decreased antibody binding 
by an average of 87% using any of three antibodies directed 
against the receptor-tethered ligand domain: ATAP2, 
ATAP87, and ATAP138 (Fig. 3A). Similar results were also 
obtained with a  fourth antibody, WEDE15, which is directed 
against  a domain of the receptor N  terminus that includes the 
putative  thrombin binding site  (not shown). By comparison, 
there was no decrease in the binding of the anti-CD9 antibody, 
BA6 (Fig. 3A), or in  antibodies directed against glycoproteins 
IIb  and  IIIa  (not shown). The loss of ATAPZ binding was not 
A. Tarver, M. Poncz, and L. Brass, unpublished observation. 
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FIG. 1. CHRF-288  cells. A ,  binding 
of radioiodinated anti-thrombin receptor 
antibody, ATAP138, to CHRF-288 cells. 
In  three such  studies the mean number 
of antibody  binding sites was 209,000 f 
6,00O/cell with  a KD of 71 -C 2 nM (mean * S.E.). B, the cytosolic free Ca2+ con- 
centration was measured in  Fura-2- 
loaded CHRF-288 after  stimulation with 
thrombin (50 nM) or  the  tethered ligand 
peptide, SFLLRN  (25 PM). In C and D, 
cells were incubated with thrombin for 
10 min, resuspended in fresh medium, 
and then stimulated with thrombin or 
SFLLRN  either 10 min or 3 h  later. 
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FIG. 2. Fluorescence  microscopy of intact CHRF-288  cells. 
After a 10-min incubation in the presence or absence of 20 nM 
thrombin, CHRF-288 cells were resuspended in fresh medium and 
incubated with either  the  thrombin receptor  antibody,  ATAP2, or  the 
CD9 antibody, BA6, followed by FITC-labeled anti-mouse secondary 
antibody. A,  resting cells with  ATAP2; B, thrombin-stimulated cells 
with ATAP2; C, resting cells with BA6; D, thrombin-stimulated cells 
with BA6. 
prevented by resuspending the  thrombin-treated cells in fresh 
medium or by adding a &fold excess of the thrombin-binding 
protein  hirudin,  indicating that  it was not due to occlusion of 
the antibody binding site by thrombin. The kinetics of recep- 
tor loss were exceedingly rapid, with  a 50% decrease occurring 
within 30 s of thrombin  addition and >85% occurring within 
1 min (Fig. 3B) .  
Internalization of Activated Thrombin Receptors-To deter- 
mine whether receptor internalization is responsible for the 
loss of activated thrombin receptors from the cell surface, 
CHRF-288 cells were incubated  with thrombin  or  SFLLRN 
and  then fixed and permeabilized before being stained with 
receptor antibody ATAP2. In unstimulated cells antibody 
binding occurred at scattered sites within the cells as well as 
60 120  180  240 300 360 420 0 60 120  180 240 300 360 420 
semnds 
. . . . . . . 
seconds 
on the cell surface (Fig. 4A and  the  first  panel of Fig. 5). The 
intracellular  sites included small punctate  structures  as well 
as larger structures with a vesicular appearance.  Exposure of 
the cells to  thrombin for 10 min prior to fixation caused a 
dramatic increase  in  both  types of intracellular  staining, par- 
ticularly in  the large vesicular structures (Fig. 4, C and D). 
Since the same changes occurred in cells activated with 
SFLLRN (Fig. 4B), they appear to not require proteolysis of 
the receptor. On the  other  hand,  there was no  intracellular 
staining, either before or  after thrombin, with the CD9 anti- 
body,  BA6 (Fig. 4, E and F )  and no binding under either  set 
of conditions of an isotype-matched  control  antibody, DA6, 
directed  against the HIV-2 glycoprotein, a 1 2 0  (not shown). 
Therefore, these results suggest that activated  thrombin 
receptors are selectively internalized from the cell surface and 
that  this process is promoted by activation of the receptor but 
does not require proteolysis of the receptor N terminus: 
The changing  distribution of the internalized  receptors over 
time is shown in Fig. 5. For these studies, CHRF-288 cells 
were fixed and permeabilized at  intervals as long as 120 min 
after  the addition of thrombin. After 1 min,  a  time by which 
antibody  binding to  the cell surface had decreased by 85%, 
ATAP2 bound predominantly to numerous punctate cyto- 
plasmic structures  that were distributed  in  a  perinuclear pat- 
tern. At this early  time point few  of the vesicular structures 
noted in Fig. 4 were visible, but by 10 min such structures 
were prominent. At 30 and 60 min, the vesicular structures 
were distributed asymmetrically, typically clustering to one 
' The conclusion that  the newly detectable  intracellular  receptors 
were initially on  the cell surface  is  also  supported by our preliminary 
observations with a monoclonal antibody whose epitope spans the 
proposed site of cleavage by thrombin. As would be predicted, this 
antibody shows an intracellular  distribution of receptors  identical to 
that in Fig. 1 (B-D),  when CHRF-288 cells are activated non- 
proteolytically  with SFLLRN  but does not recognize the intracellular 
receptors in cells activated by thrombin (L. Brass, S. Pizarro, M. 
Ahuja, E. Belmonte, J. Stadel, and J. Hoxie, unpublished observa- 
tions). 
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FIG. 3. Flow cytometric analysis of antibody binding to 
CHRF-288 cells. A,  CHRF-288 cells were incubated for 10 min in 
the absence (solid bars) or presence (hatched bars) of 50 nM thrombin, 
followed by one of the monoclonal antibodies shown and FITC- 
labeled anti-mouse  secondary  antibody. The cells were then analyzed 
by flow cytometry to quantitate cell surface fluorescence. ATAPP, 
ATAP87, and ATAP138 are  anti-thrombin-receptor antibodies. BA6 
is an  anti-CD9 antibody. P3 is  an isotype-matched control murine 
monoclonal antibody. The results shown are from 4-8 determinations 
expressed as mean +. S.E. B, CHRF-288 cells were fixed and  stained 
with antibody ATAP2 or ATAP138 after incubation with 50 nM 
thrombin for the  times shown. The  results  are  the mean +. S.E. of 4 
studies. 
side of the nucleus. By 120 min fluorescence of structures  in 
the cytoplasm had generally decreased, but  there was a  dis- 
cernible increase in cell surface fluorescence, a  result subse- 
quently confirmed by  flow cytometry of recovering cells (see 
below). 
Localization of the  Internalized Receptors-To identify the 
cellular compartments involved in  thrombin receptor inter- 
nalization, co-localization studies were performed with two 
other monoclonal antibodies: RPN511, which binds to the 
human transferrin receptor and was used as a marker for 
endosomes (27, 28); and H4A3, which recognizes the lyso- 
some-associated membrane  protein, LAMP-1, and was used 
to identify lysosomes (20). Fig. 6 shows a  paired exposure of 
CHRF-288 cells that were fixed and permeabilized after a 1- 
min incubation  with thrombin  and  stained with ATAPZ (top) 
and RPN511 (bottom). The  punctate perinuclear structures 
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FIG. 4. Fluorescence microscopy of permeabilized CHRF- 
288 cells. CHRF-288 cells were incubated for 10 min at 37 "C with 
50 nM thrombin or 50 p~ SFLLRN,  then washed, fixed, and perme- 
abilized with methanol/acetone and  stained with  primary  antibody. 
A, control cells with thrombin receptor  antibody ATAPP; B, 
SFLLRN-treated cells with antibody ATAP2; C and D, thrombin- 
treated cells with antibody ATAP2; E, control cells with anti-CD9 
antibody BA6; F, thrombin-treated cells with  antibody BA6. 
typically seen with ATAP2 at  this early  time  point were also 
recognized by the  transferrin receptor antibody. These  partic- 
ular structures were not, however, detectable with the  anti- 
LAMP-1  antibody, H4A3 (not shown). Fig. 7 shows a paired 
exposure when the CHRF-288 cells were stained with ATAP2 
(top)  and H4A3 (bottom) 30 min after  the addition of throm- 
bin. At this time point  the  compartments recognized by the 
two antibodies overlapped, with the vesicular structures rec- 
ognized by the  thrombin receptor antibody  clustering  around 
the region of anti-LAMP-1  staining  and, in some, but not all, 
cases binding both antibodies. These results indicate that 
activated thrombin receptors are rapidly incorporated into 
endosomes and  then more slowly transported  into lysosomes. 
Entry of Receptors through Coated Pits in  the  Plasma Mem- 
brane-Immunoelectron microscopy was used to examine the 
initial steps of thrombin receptor internalization. In  the  stud- 
ies shown in Fig. 8, CHRF-288 cells were incubated with 
thrombin for 1 min at  37 "C, then labeled at  4 "C with anti- 
body ATAP2 followed by gold-conjugated secondary antibody. 
One minute after  the addition of thrombin, clusters of recep- 
tors were seen  in and  around  pits within the plasma mem- 
brane  that resemble typical  clathrin-coated  pits. There was 
no  clustering of receptors in non-coated  pits, even at longer 
times. The involvement of coated pits in thrombin receptor 
internalization is similar to  that recently reported for lutropin 
hormone (LH) receptors  (29) but  contrasts with the results 
of studies on @-adrenergic receptors, where internalization 
appears to involve non-coated pits  (30), suggesting that dis- 
tinct mechanisms for internalization may  be utilized by dif- 
ferent G protein-coupled receptors. 
Recycling of Activated Thrombin Receptors-As  was noted 
earlier,  CHRF-288 and  HEL cells that have been desensitized 
by thrombin recover 30-40%  of their initial responsiveness to 
SFLLRN over a period of 2-3 h (Fig. 1 and Ref. 17), but 
during the same period there is no recovery of the response 
to  thrombin.  This early  phase of recovery of the  SFLLRN 
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FIG. 5. Time  course of thrombin  receptor  internalization. CHRF-288 cells were incubated at 37 “C for  up to 120 min. Thrombin (20 
nM or approximately 2 units/ml) was added at  time zero. Hirudin (10 units/ml) was added after 10 min to remove any  thrombin  still bound 
to  the cell surface. At  each time shown, aliquots of the cell suspension were washed, fixed with methanol/acetone, and  then stained with 
thrombin receptor antibody, ATAP2. 
FIG. 6. Co-localization of antibodies  directed against 
thrombin  receptors  and  transferrin  receptors  after 1 min with 
thrombin. CHRF-288 cells were incubated with thrombin (20 nM) 
for 1 min at 37 “C  and  then stained with thrombin receptor antibody 
ATAP2 and  the anti-transferrin receptor antibody RPN511, as de- 
scribed under “Experimental Procedures.” A, fluorescence from the 
FITC-conjugated ATAP2; B, fluorescence from the transferrin recep- 
tor antibody detected with rhodamine-conjugated secondary anti- 
body. The filled and open arrows point to two pairs of cells in which 
the location of the two antibodies can be compared. 
response is unaffected by cycloheximide, suggesting that  it 
does not require receptor synthesis (17). Since the present 
studies show that activated thrombin receptors are rapidly 
internalized, we next tested whether the recovery of respon- 
siveness to  SFLLRN coincides with the reemergence of recep- 
tors on the cell surface. Fig. 9 shows the results that were 
obtained. In these studies CHRF-288 cells were incubated 
briefly with thrombin, after which the recovery of SFLLRN- 
induced changes in cytosolic Ca2+ was compared with the 
recovery of receptors on the cell surface measured by flow 
cytometry. On these cells, the initial exposure to  thrombin 
FIG. 7. Co-localization of antibodies  directed against 
thrombin  receptors  and LAMP-1 af ter  30 min  with  thrombin. 
CHRF-288 cells were incubated with 20 nM thrombin for 30 min at 
37 “C and  then stained with thrombin receptor antibody ATAPP and 
the monoclonal antibody H4A3, an antibody specific for the lysosomal 
membrane protein LAMP-1. A, fluorescence from the FITC-conju- 
gated ATAP2; B, fluorescence from the anti-LAMP-1 antibody de- 
tected with rhodamine-conjugated secondary antibody. In the cell 
indicated by the filled arrows, the large ring visible to  the left of the 
nucleus with the thrombin receptor antibody is not stained by the 
LAMP-1 antibody. In  the cell indicated by the open arrows, several 
vesicles at  the top of the cell are  stained by both antibodies. 
caused a 90% decrease in both antibody binding and the 
magnitude of the SFLLRN-induced increase in  intracellular 
Ca2+. Over the next 3 h the peptide-induced Caz+ signal 
recovered to approximately 40% of its simultaneous value in 
control cells and antibody binding recovered to approximately 
30% of its initial value. The  rates of recovery of the two events 
were similar,  although at  the earliest  time points  the recovery 
of antibody binding sites preceded the recovery of the Ca2+ 
signal. Identical results were obtained with anti-thrombin 
receptor antibody  WEDE15 (not shown). Since there was no 
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FIG. 9. Recovery of thrombin receptors  and SFLLRN re- 
sponses in CHRF-288  cells desensitized with thrombin. CHRF- 
288 cells were incubated with 50 nM thrombin for 10 min at 37 "C. 
At each time indicated one of two assays were performed  either 10 
PM SFLLRN was added and  the subsequent increase in cytosolic free 
Caz+ was measured using Fura-2 fluorescence (open symbols) or the 
binding of ATAP2 and ATAP138 to the cell surface were measured 
by  flow cytometry (closed symbols). The results shown are  the mean 
& S.E. of 10 Ca2+ determinations and 4 antibody measurements and 
are expressed as  a percentage of the results  obtained with the non- 
thrombin-treated cells at  the same time. 
FIG. 8. Electron microscopy of thrombin-stimulated CHRF- 
288 cells. CHRF-288 cells were incubated with 50 nM thrombin for 
1 min at 37 "C. Surface receptors were detected by incubating the 
cells with antibody ATAP2 followed by secondary antibodies adsorbed 
to 5-nm gold at 4 "C. Four representative images of the plasma 
membrane are shown. Inpanels A-C, gold particles are seen clustering 
in or near coated pits.  Panel D shows a surface invagination connected 
by a  tubule  out of the plane of the section with a coated pit attached. 
recovery of the  thrombin response during  this period, these 
results suggest that the more rapid recovery of SFLLRN 
responsiveness is due to  the reemergence of previously inter- 
nalized receptors that  are unable to  interact with thrombin a 
second time. 
DISCUSSION 
Prior to the publication of the cloned sequence of the 
thrombin receptor, little was known about  the mechanisms 
by which it is activated and inactivated. It was clear, however, 
that  at least some of the cellular effects of thrombin involve 
G proteins and  that, like other receptors which interact with 
G proteins, thrombin receptors are subject to homologous 
desensitization. These effects could be demonstrated with 
platelets but were best observed with cells in which exposure 
to thrombin is  not a terminal event. For example, we found 
that  HEL cell thrombin  receptors undergo homologous desen- 
sitization and that this process does not require receptor 
proteolysis since it could also be observed with SFLLRN- 
containing  peptides  (17). In  those studies recovery from the 
desensitized state evoked by thrombin occurred in two distinct 
phases. The first was detectable within 30 min and lasted 
several hours. During this period the cells responded to 
SFLLRN but not thrombin. This phase of recovery was 
unaffected by cycloheximide but could be delayed by inhibi- 
tors of serine/threonine  phosphatases such as calyculin and 
okadaic acid, suggesting that receptor expression may be 
modulated by phosphorylation, either of the receptor itself or 
an associated protein (17). The second phase of recovery 
required up  to 20 h to complete and could be  inhibited  with 
cycloheximide. This phase  restored the full thrombin response 
and presumably reflects the resynthesis and surface expres- 
sion of new receptors. 
In  the  present studies we have extended these earlier ob- 
servations by examining the role of receptor internalization 
and recycling in the loss and subsequent recovery of thrombin 
responses. Both of the cell lines that were studied express 
large numbers of functional thrombin receptors at  a  density 
similar to platelets, and  in  both cell lines thrombin responses 
were subject to homologous desensitization. Since  thrombin 
binding  studies have been hampered by the ability of thrombin 
to bind  with high affinity to cell surface proteins other  than 
its receptor, monoclonal antibodies rather than labeled li- 
gands were used to detect and track the receptor. These 
antibodies  bind to  both  the  intact  and  the thrombin-cleaved 
forms of the  thrombin receptor, making it possible to locate 
the receptor before and  after activation. 
The results show that activated thrombin receptors are 
internalized at  a rate  that is as  fast  or  faster  than  the time 
required to  demonstrate desensitization of receptor function. 
Within 1 min of activation, thrombin receptors were clustered 
in and around coated pits in the plasma membrane, after 
which they passed through at  least three morphologically 
distinguishable cytoplasmic structures. The first, which had 
a punctate appearance by fluorescence microscopy, also con- 
tained  transferrin receptors and presumably represents  early 
endosomes. The second, which had a vesicular appearance, 
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was variably stained with the anti-LAMP-1 antibody and 
probably represents  late endosomes or prelysosomes. These 
were detectable within 10 min of the addition of thrombin. 
The final structures, which were visible as early as 30 min, 
were intensely stained by the  anti-LAMP-1 antibody and  are 
presumably mature lysosomes. At  approximately the same 
time that thrombin receptors could be detected in lysosomes, 
there was also a detectable recovery of antibody binding sites 
on  the cell surface. Over a  2-h period the number of receptors 
on  the surface of CHRF-288 cells returned to approximately 
30% of its original value. This recovery paralleled the recovery 
of receptor function when the cells were stimulated with 
SFLLRN  and coincided with the  first phase of receptor resen- 
sitization during which the cells were unable to respond to 
thrombin. 
A Model for Receptor Internalization and Recycling-Col- 
lectively, these observations suggest a working model for 
receptor internalization and recycling that accounts for the 
present observations and suggests directions that can be taken 
in  future  studies (Fig. 10). According to  this model, thrombin 
receptors are  internalized  shortly  after  they are activated. The 
majority of the internalized receptors are  sorted to lysosomes 
and presumably destroyed. However, approximately 25% are 
recycled back to  the cell surface. It is the recycling of previ- 
ously activated (and presumably cleaved) receptors that ap- 
pears to account for the cycloheximide-resistant early phase 
El 
Intact Cleaved 
(active) 
h 
FIG. 10. A working model for thrombin  receptor  internali- 
zation and recycling. Intact thrombin receptors on the surface of 
responsive cells ( I  ) are  activated by proteolysis of the N terminus 
initiating G protein-mediated  events  such as  the activation of phos- 
pholipase C B  (2) .  This is followed by receptor internalization which 
requires activation, but not proteolysis, of the receptor (3). Receptor 
phosphorylation (*) may occur at  the same time. Once internalized, 
approximately 75% of the thrombin receptors on CHRF-288 cells are 
transferred to lysosomes and degraded ( 4 ) ,  while approximately 25% 
are recycled to  the cell surface, possibly after dephosphorylation (5). 
The recycled, thrombin-activated receptors are unable to respond to 
thrombin  a second time but retain their ability to be activated by 
exogenous peptides containing the critical SFLLRN sequence. Re- 
sponsiveness to thrombin is restored by the synthesis of  new receptors 
( 6 ) .  
of recovery during which the cells respond to SFLLRN  but 
not  thrombin. This discrepancy between the recovery of the 
SFLLRN  and  thrombin responses in thrombin-desensitized 
cells is a consequence of the novel mechanism by which 
thrombin  activates its receptors. On the  other hand,  as would 
be predicted by the model, when the receptors are initially 
activated (and desensitized) by SFLLRN,  the recovery of the 
thrombin  and  SFLLRN responses occurs equally rapidly (17), 
presumably because in this case the recycled receptors are 
intact  and  therefore capable of responding to either agonist. 
Regardless of whether the cells are initially desensitized by 
thrombin  or  SFLLRN, the recycled receptors are insufficient 
to restore full responses. Complete recovery occurs only after 
the cells synthesize new receptors and express them on their 
surfaces. Since some staining of lysosomal structures by the 
receptor-directed antibodies was seen even in  “resting” 
CHRF-288 cells, there may be a much slower rate of consti- 
tutive  internalization  and  perhaps recycling of receptors even 
in  the absence of thrombin  stimulation. 
Although not previously demonstrated for thrombin recep- 
tors, agonist-induced internalization has been studied with 
several other members of the G protein-coupled family of 
receptors, including 8-adrenergic (18), muscarinic cholinergic 
(31), and  LH receptors (29). For 8-adrenergic receptors, loss 
of receptor function is generally placed in  the context of three 
overlapping events: desensitization (loss of receptor-mediated 
responses), sequestration (loss of ligand binding sites from 
the cell surface), and down-regulation (loss of binding sites 
for membrane-permeable ligands). Although much of the  data 
on &adrenergic receptor internalization  has been obtained by 
comparing the binding of membrane-permeable and mem- 
brane-impermeable agonists, von Zastrow and Kobilka (19) 
have recently used receptor-directed antibodies to track the 
movement of @-adrenergic receptors stably  transfected  into 
human embryonic kidney 293  cells. Their  results show that 
8-adrenergic receptors internalize within 5-10 min of agonist 
addition and  return  to  the cell surface within 30 min of agonist 
removal. In between, the receptors passed through an intra- 
cellular compartment that,  as observed in  the present studies, 
also contained  transferrin receptors. 
Although these  results with 8-adrenergic receptors are in 
some ways similar to those  obtained with thrombin receptors, 
further comparisons point out several striking differences 
even among the relatively small number of G protein-coupled 
receptors that have been examined. These include differences 
in  the  rate  and  extent of internalization, as well as in the 
ultimate  fate of the internalized receptors, all of which may 
reflect differences in  the role of internalization and recycling 
as regulators of receptor function. For example, although the 
numbers vary, typically only 25-50%  of activated @adrenergic 
receptors (32, 33), muscarinic receptors (31), and  LH recep- 
tors (29) are internalized. In contrast, we found that essen- 
tially all of the activated  thrombin receptors on CHRF-288 
and  HEL cells are internalized. Second, of the @-adrenergic 
receptors that  are internalized, nearly all are recycled unless 
the agonist remains  present for longer than 60 min, in which 
case an increasing fraction of the receptors are degraded (33). 
By comparison, we found that  the majority of internalized 
thrombin receptors are degraded, as are internalized LH 
receptors (29).  Third,  although recycled 8-adrenergic recep- 
tors  are responsive to their  natural agonists, recycled throm- 
bin receptors are unresponsive to thrombin, even though their 
ability to be reactivated  SFLLRN shows that they  are  other- 
wise intact. Finally, differences may exist in the route by 
which G protein-coupled receptors are internalized; thrombin 
receptors (the present studies) and LH receptors (29) are 
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internalized  through coated pits, whereas @-adrenergic recep- 
tors have been reported to be internalized  through  non-coated 
pits (30). Whether this particular difference is entirely recep- 
tor-specific, as opposed to cell-specific, remains to be deter- 
mined, but  as  is discussed below, it has implications for the 
mechanism of internalization. 
Additional Issues-The proposed model for thrombin recep- 
tor internalization and recycling shown in Fig. 10 raises a 
number of issues for future investigation. First,  what  are  the 
signals that trigger receptor internalization? Presumably not 
proteolysis of the N terminus since receptors activated by 
SFLLRN are internalized as readily as those activated by 
thrombin. Receptor phosphorylation may be one such trigger, 
but at the moment the evidence that activated thrombin 
receptors become phosphorylated is still indirect. A related 
issue is whether thrombin receptor desensitization is due 
solely to receptor internalization or, as  has been shown for p- 
adrenergic receptors, desensitization can occur even when 
internalization  is blocked by mutating  the receptor or  inhib- 
iting endocytosis (32-35). Interestingly,  in the study by Yu et 
al. (33), blockade of internalization  prevented resensitization 
of the p-adrenergic receptors, implying that processing of the 
internalized receptors, possibly by phosphatases, might be 
required for recovery of function. Our data with thrombin 
receptors are  consistent this  interpretation. 
Second, what role does the  structure of the thrombin recep- 
tor play in  the mechanism of internalization? Based upon 
analogies with other proteins, the clustering of activated 
thrombin receptors in  clathrin-coated  pits could be directed 
by specific sites within the cytoplasmic domains of the recep- 
tor. For a number of other receptors these internalization 
motifs are characterized by an aromatic  amino acid, usually a 
tyrosine, presented in the context of a  tight  turn (27). The 
existence of signal sequences within the cytosolic domains of 
G protein-coupled receptors has  not been clearly established, 
but tyrosine residues have been implicated in  the  internali- 
zation of &adrenergic receptors (36) and several such resi- 
dues are  present in the  tail of the thrombin receptor. Inter- 
nalization may also require the activation-dependent associ- 
ation of one or more accessory molecules with the thrombin 
receptor, such as  the adaptor  proteins that help to form the 
clathrin cage  when mannose 6-phosphate/insulin-like growth 
factor I1 receptors and asialoglycoprotein receptors are  inter- 
nalized (27, 37, 38). 
A third issue is the biological role of the recycled thrombin 
receptors, particularly since they do not respond to thrombin. 
Might peptides generated at  the site of vascular injury reac- 
tivate  these receptors leading to long term effects on the cell? 
Finally, why do recycled receptors not self-activate? Their 
ability to respond to SFLLRN suggests that they  are coupled 
to G proteins. Why does the  tethered ligand not  reactivate 
the receptor? One possibility is that  the N  terminus of the 
receptor has undergone additional proteolytic processing. Pro- 
teolysis by plasma peptidases has been proposed (39),  but the 
slow rate of that process relative to the short time that 
activated  thrombin receptors remain on the cell surface makes 
intracellular processing more likely. Studies with peptides 
mimicking the tethered ligand domain suggest that  the re- 
moval of the N-terminal  serine residue would  be sufficient to 
render it inactive, but proof that  this occurs awaits the phys- 
ical isolation and sequencing of the recycled receptors. Since 
antibody ATAP2 recognizes an epitope within the first 8 
residues of the neo-N  terminus, it is unlikely that a  substantial 
portion of this region can have been removed. An alternative 
possibility is  that thrombin  has to be present to promote the 
interaction between the  tethered ligand and remainder of the 
receptor immediately after receptor cleavage. 
In conclusion, the studies presented in this manuscript 
show that activated  thrombin receptors are removed from the 
surface of HEL  and CHRF-288 cells with remarkable rapidity 
and largely, but  not  entirely, destroyed. This process of inter- 
nalization and recycling is at least  partly responsible for the 
loss and recovery of thrombin receptor function observed 
when thrombin receptors are activated. Whether internali- 
zation is solely responsible for desensitization and whether 
internalization also occurs on other thrombin-responsive cells 
is a subject of considerable interest,  as is the role played by 
these processes in the biology of other vascular cells. 
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